Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold Nanotechnology has shifted the paradigm of anticancer drug delivery. Small-molecule drugs packed in nanoparticles can improve their solubility, protect them from premature degradation, prolong blood circulation and enhance tumor accumulation through the enhanced permeability and retention effect [1] [2] [3] . Moreover, with various tumor-targeting molecules (antibodies, peptides and nucleic acids), nanoparticles can achieve active tumor targeting [4] [5] [6] [7] . Numerous studies have demonstrated that by using specific targeting ligands or by tumor-specific biomarker activation, the drug delivery efficiency to targeted tumor tissues is signifi cantly increased, resultis significantly increased, resulting in an improved therapeutic index, hence better therapeutic efficacy [1, 8] . However, such an effect is often the direct result of the relative increase of the drug uptake in tumor versus normal tissue ratio and rarely leads to the absolute decrease of drug distribution in normal tissues. Therefore, these agents will still encounter side effects such as bone marrow suppression, gastric erosion, renal toxicity, cardiomyopathy and neurotoxicity [9] . Attenuation of drug toxicity to non targeted tissues (protecting normal tissues from collateral damage) is another important direction to improve therapeutic index and drug efficacy. Selective protection of nontargeted cells requires nanoparticle carriers to shield the encaps nanoparticle carriers to shield the encapcarriers to shield the encapto shield the encapto shield the encapshield the encapthe encapsulated toxic payloads from nonspecific uptake or premature release until they reach targeted cells. Selective protection of normal cells will reduce systemic side effects and increase clinical tolerable dose, which will ultimately improve the impact of chemotherapy. The goal of this study was to explore the utility of a new nanoparticle carrier in protecting nontargeted cells while asserting toxicity against targeted cells.
We recently introduced a high-density lipoprorecently introduced a high-density lipoprointroduced a high-density lipoprohigh-density lipoprotein (HDL)-mimicking peptide-phospholipid nanoscaffold (HPPS) as a powerful vehicle for direct cytosolic payload delivery, thus bypassing the formidable threat posed by the endosomal trapping of drug carriers [10] . HPPS is composed of the phospholipid, cholesteryl oleate and an amphipathic a-helical peptide, apolipoprotein A-1 (ApoA-1) mimetic, which are all highly biocompatible [11] [12] [13] . The interaction between the self-assembled peptide network and the colloidal phospholipid monolayer enables HPPS to mimic the behavior of plasma-derived HDL in both its structural and functional properties (e.g., size, lipophilic payload, scavenger receptor class B type 1 [SRB1] specificity and pharmacokinetics) [10] . Like spherical HDL, HPPS is highly monodisperse with a distinct sub-30-nm coreshell structure; thus, it is able to diffuse freely through interstitial spaces (<40 nm) [14] , a key advantage for the enhancement of both accumulation and internalization in solid tumors [10] . HPPS also mimics the plasma HDL in its long circulation half-life and its ability to target the SRB1 [10] , which is overexpressed on a number of tumor cells [15] [16] [17] . The SRB1 pathway is parThe SRB1 pathway is particularly attractive for anticancer drug delivery because it mediates the selective transport of Research in the development of nanoscale drug carriers primarily focuses on maximizing drug delivery efficiency to tumor tissues. However, less attention has been given to minimizing drug toxicity to nontargeted cells to enhance therapeutic selectivity. Aim: Herein, we report on the use of a newly developed high-density lipoprotein-mimicking peptide-phospholipid nanoscaffold (HPPS) to deliver a lipophilic drug, paclitaxel oleate (PTXOL). Method & Results: The formulated PTXOL HPPS (120:1) drastically increased therapeutic selectivity by reducing cytotoxicity of PTXOL to nontargeted cells. Using mice bearing targeted (KB) and nontargeted (HT1080) tumors as models, we demonstrated that tumor volume of nontargeted cells was decreased to 57% by PTXOL treatment but increased to 1220% by PTXOL HPPS treatment. However, upon treatment of paclitaxel, PTXOL and PTXOL HPPS, tumor volumes of targeted groups were reduced to 85, 50 and 63%, respectively. Conclusion: These data strongly suggest that HPPS can attenuate toxicity of anticancer drugs to nontargeted cells, resulting in cell-killing efficacy only on targeted cells. cholesterol esters from HDL directly into the cytosol of targeted cells [18, 19] . We have shown that HPPS is capable of exploiting this unique nonendocytic uptake mechanism for the direct cytosolic payload delivery [10] . In addition, HPPS exhibits effective shielding properties that could protect the payload before it enters the targeted cells [10] . Finally, HPPS is a modular platform with the capability to carry a range of diagnostic and therapeutic payload molecules and versatile tumor-targeting ligands. Together, these features resulted in a simple and robust nanocara simple and robust nanocara simple and robust nanocarrier for efficient tumor-targeted drug delivery. We hypothesized that using HPPS for anticancer drug delivery could enhance targeting therapy, not only by an effective therapeutic effect to targeted cells, but also by attenuating toxicity to normal tissues. To test this hypothesis, our study design features the following drug selection and in vitro and in vivo models.
Drug selection
A lipophilic prodrug of paclitaxel (PTX), PTX oleate (PTXOL) [20, 21] , is used as a prototype drug to be loaded into HPPS as depicted in Figure 1A . This prodrug releases PTX with facile enzymatic hydrolysis of the fatty acid esters and causes cell death by disrupting the normal microtubule dynamics required for cell division [21] . The lipid anchor of PTXOL is expected to enable its stable incorporation into the hydrophobic core of HPPS.
In vitro & in vivo models
A human KB cell line (KB), which expresses a high level of SRB1 (SRB1 + ), was selected as the targeted cell to investigate the therapeutic effect of the PTXOL-loaded HPPS, denoted as PTXOL HPPS. A human fibro sarcoma cell line (HT1080), which has a low level of SRB1 (SRB1 -) expression was chosen as the non targeted cell to investigate the protective function of PTXOL HPPS. Chemotherapeutic drugs often damage cells by interfering with DNA replication or cellular metabolism. Thus, tumor cells, which proliferate much faster than normal cells, are more sensitive to drug damage [22] . Therefore, if HPPS can attenuate the toxicity of PTXOL to nontargeted tumor cells, it will provide strong evidence for its protective function for nontargeted normal cells. [21, 23] . KB (SRB1 + ) and HT1080 (SRB1 -) cell lines were purchased from the American Type Culture Collection.
n Nanoparticles preparation High-density lipoprotein-mimicking peptidephospholipid nanoscaffold and DiRBOA-loaded HPPS (DiRBOA HPPS) was prepared using previously described methods [10] . PTXOLloaded HPPS (PTXOL HPPS) was prepared by combining 3 µmol DMPC, 0.1 µmol CO and 0.4 µmol PTXOL in 200 µl of chloroform and mixed for 5 min. The mixture was then dried under a stream of nitrogen gas to form a thin lipid film and further dried under vacuum for 1 h. A total of 1 ml of phosphate-buffered saline (PBS, pH 7.5) was added to the dried lipid film, followed by vortexing for 5 min and sonication under 48°C for 1 h. The turbid emulsion became transparent after adding 2 mg of AP (dissolved in 1 ml PBS) and was stored at 4°C overnight. The mixture was then purifi ed by size exclumixture was then purified by size exclusion chromatography (HiLoad 16/60 Superdex 200 pg, GE Healthcare) with Tris buffered saline (10 mM Tris-HCl, 0.15 M NaCl, 1 mM EDTA, pH 7.5) at a flow rate of 1 ml·min -1 . Fractions at the retention time from 55 to 65 min were collected and concentrated using a centrifugal filter device (10,000 MW, Amicon, Millipore). The resulting PTXOL HPPS was stored under 4°C until use (SupplementAry Figure 1A , see online www.futuremedicine.com/doi/suppl/10.2217/ nnm.11.10).
n Characterization of PTXOL HPPS
Determination of nanoparticle compositions
The molar concentrations of DMPC, CO and AP were determined using a previously reported method [10] . A reverse-phase high-performance liquid chromatography protocol was developed to quantify the molar concentration of PTXOL in HPPS. First, the retention time of PTXOL was determined by a HPLC mass spectromety system (Waters 2695 controller with a 2996 photo diode array detector and a Waters ZQ™ mass detector, USA) using the following method: solvent A = 0.1% trifluoroacetic acid in water, solvent B = acetonitrile; gradient: from 60% A + 40% B to 50% A + 50% B for 5 min, then to 20% A + 80% B for 30 min and further to 100% B for 5 min; flow rate: 0.5 ml.min -1 . Samples were run on a Waters XBridge™-C3 column (2.5 µm, 4.6 × 150 mm) and absorbance was read at 229 nm. PTXOL had a column retention time of approximately 35.8 min identified by the corresponding ESI-Mass (cal. 1118.4, found 1118.7, SupplementAry Figure 1B ). The area under the peak was calculated using numerical integration (Simpson's rule). A standard curve was then made using known amounts of PTXOL in dimethylformamide. To determine the PTXOL payload in the formulation, PTXOL was extracted from the nanoparticle by using organic solvent extraction. Briefly, 100 µl of PTXOL HPPS was extracted with 300 µl of chloroform, vortexed for 3 min, and then centrifuged at 12,000 rpm for 10 min. The organic phase was collected, dried, redissolved in dimethylformamide and injected into the HPLC mass spectrometry for quantification of the PTXOL concentration (C PTXOL ). The payload of PTXOL per HPPS was determined with equAtion 1: Payload (mol/mol) = C PTXOL × N/C DMPC. (C DMPC : molar concentration of DMPC; N: number of DMPC molecules per HPPS particle)
Morphology & size measurement
Transmission electron microscopy was performed on a modern Hitachi H-7000 transmission electron microscope (Hitachi, Inc., Japan) equipped with a digital image acquisition system to determine the morphology and size dispersion of PTXOL HPPS stained with 2% uranyl acetate. The particle size distributions of PTXOL HPPS was measured by dynamic light scattering photon correlation spectroscopy (Zetasizer Nano-ZS90; Malvern Instruments, UK) utilizing a 4.0 mW He-Ne laser operating at 633 nm and a detector angle of 90°.
n Flow cytometry study Human KB and HT1080 cells were incubated in RPMI 1640 supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 . Cells were seeded in sixwell plates at a density of 2 × 10 5 cells per well and incubated for 24 h at 37°C in an atmosphere of 5% CO 2 in a humidified incubator. The medium was removed and the cells were rinsed with PBS. The cells were then incubated with 10 µM of DiRBOA HPPS for 5 min, 10 min, 20 min, 30 min, 1 h, 3 h, 6 h, 12 h and 16 h, respectively. After removal of DiRBOA HPPS, cells were incubated further in culture medium to 24 h then transferred to a 15 ml centrifuge tube with 2 ml of PBS. Subsequently, cells were centrifuged at 1300 rpm for 6 min and the PBS was removed. This rinsing procedure was repeated three times. The cells were then fixed by 2% paraformaldehyde solution for 10 min. After fixing, the cells were centrifuged and rinsed with PBS twice. The fluorescence intensities of the cells were measured by a Cytomics FC 500 series flow cytometry system from Beckman Coulter (excitation: 633 nm; emission: 660-690 nm). Autofluorescence from the untreated cells was minimal. The maximum cell number count was 10,000 for all samples.
n In vitro toxicity study In vitro toxicity of PTXOL HPPS was determined on KB and HT1080 cells and quantified by standard MTT assays [24] . Cells were seeded in a 96-well plate at a density of 8000 cells per well. Once cells reached 80% confluence, the medium was replaced with 200 µl culture medium containing PTX (8 µM), PTXOL (8 µM), PTXOL HPPS (containing PTXOL 8 µM and HPPS 0.07 µM), PTXOL HPPS with 20-fold molar excess of HDL (containof HDL (contain-HDL (contain-(containing PTXOL 8 µM, HPPS 0.07 µM and HDL 1.4 µM), and HPPS (0.07 µM). One row of the 96-well plates was used as a control with 200 µl culture medium only. After 6 h incubation, the drug solutions were removed and the cells were washed twice with PBS and allowed to grow for an additional 42 h. The MTT compound was then added to the medium at 0.5 mg·ml 
Tumor volume change = (volume current -volume initial )/volume initial ×100% (volume current : current tumor volume. volume initial : initial tumor volume before treatment)
n In vivo toxicity study of HPPS To assess the tolerability of HPPS, 2000 mg·kg -1 HPPS (based on phospholipid concentration) was given to five nude mice (female, 6-7 weeks old) through the tail vein and 0.5 ml saline were given to the other five mice as controls. After injection, mice were monitored for health and the body weights were measured every 3 days. At 1, 8 and 15 days postinjection, blood samples (200 µl each) were collected from the saphenous vein to test peripheral blood cells and liver function. At 21 days postinjection, mice were sacrificed and their organs (heart, liver, spleen, kidney and lung) were excised, fixed in 10% formalin, embedded in paraffin, sectioned and stained with hematoxylin and eosin for histological ana lysis.
n Statistical analysis The Student's t-test (two tailed) was used to determine significant differences between in vitro and in vivo anti-tumor efficacy in experiments. P-values less than 0.05 were considered significant.
Results
n Synthesis & characterization of PTXOL HPPS nanoparticles Paclitaxel oleate, a lipophilic derivative of PTX, was used as a prototype drug to evaluate the drug delivery capacity of HPPS. The PTXOL HPPS formulation was prepared and optimized by changing the ratio of PTXOL to phospholipids. As shown in Figure 1B , the increase of PTXOL to lipid ratio led to the increase of PTXOL payload, which reached maximum when the ratio exceeded 4:30. Meanwhile, the PTXOL entrapment efficiency continuously decreased with an increase in the PTXOL to lipid ratio. Thus, the 4:30 PTXOL to lipid ratio was selected for the preparation of PTXOL HPPS for all subsequent studies because of its relatively high payload and good entrapment efficiency. The resultant PTXOL HPPS formulation contained 120 PTXOL per particle (mol/mol) and its PTXOL recovery was determined to be 51.9% from the starting material. The transmission emission microscopy data ( Figure 1C) showed that the PTXOL HPPS formed a mono dispersed spherical particle with a diameter of 21.8 ± 3.4 nm (dynamic light scattering data, SupplementAry Figure 1C ). HPPS and fluorescent DiRBOA HPPS were also prepared as controls, according to the previously reported protocol [10] , to reaffirm its intracellular delivery mechanism and to provide guidance for setting the treatment protocols through its fluorescent properties.
n Differential kinetics of HPPS payload delivery in target versus nontargeted cells We have previously demonstrated that HPPS can deliver payload specifically to SRB1 + cells by confocal imaging using fluorescently labelled DiRBOA HPPS [10] . To further understand this interaction, we studied the kinetics of HPPS payload delivery using flow cytometry in KB (SRB1 + ) cells versus HT1080 (SRB1 -) cells with a surrogate fluorescent payload (DiRBOA). All cell-associated fluroescence was normalized to the saturated fluorescence signal of DiRBOA HPPS in KB cells. The results indicated that the fluorescence associated with KB cells upon DiRBOA HPPS treatment was rapid, reaching 60 and 93% of maximum cell-associated fluorescence after 30 min and 6 h, respectively (Figure 2 ). In comparison, there was limited association observed by HT1080 cells and this process proby HT1080 cells and this process pro-HT1080 cells and this process pro-HT1080 cells and this process procells and this process proceeded over an extended period of time. This association was found to be less than 7% at the 30 min time point and did not become saturated after 16 h of incubation. Based on the above flow cytometry results, we found 6 h to be the shortest incubation time to observe maximal binding to KB cells and equated to a 5.4-fold greater association when compared with HT1080 cells.
For these reasons, we utilized 6 h as the optimal incubation time for subsequent PTXOL HPPS efficacy studies.
n Selective in vitro cytotoxicity of PTXOL HPPS to targeted versus nontargeted cells After validating the differential kinetics of HPPS payload delivery and determining the optimal drug incubation time point, we next studied the selective cytotoxicity of PTXOL HPPS on KB (SRB1 + ) and HT1080 (SRB1 -) cells, where PTX, PTXOL and HPPS were used as controls. As shown in Figure 3 , HPPS alone (vehicle control) did not show any toxicity to cells in the experitoxicity to cells in the experity to cells in the experito cells in the experiin the experiment. The drug controls, PTX and PTXOL induced very similar cell toxicity to either KB or HT1080 cells, suggesting that the PTXOL prodrug can generate similar anti-tumor efficacy as PTX. Compared with KB cells, HT1080 cells were found to be more sensitive to PTX and PTXOL treatments. Upon PTX treatment, cell viabilities of KB and HT1080 cells were 45 and 12%, respectively. Upon PTXOL treatment, cell viabilities in KB and HT1080 cells were 42 and 6%, respectively. Loading PTXOL into HPPS significantly decreased the cytotoxicity of PTXOL HPPS to nontargeted HT1080 cells (p < 0.01) (the cell viability was 6% for PTXOL treatment and 91% for PTXOL HPPS treatment). This is a clear indication that HPPS is able to shield PTXOL from non targeted cells (HT1080). Nevertheless, PTXOL HPPS maintained its therapeutic effect against targeted cells (35%) since it induced similar toxicity in KB cells as the free PTX (45%) or PTXOL (42%) did. Moreover, this therapeutic effect was blocked by a 20-fold excess of native HDL. The aforementioned data strongly suggests that HPPS can effectively deliver drug to cells through the SRB1-mediated pathway and can effectively attenuate toxicity of anticancer drugs to nontargeted cells, but retain its cytotoxicity against targeted cells.
n Selective in vivo anti-tumor efficacy of PTXOL HPPS to targeted versus nontargeted cells
The in vivo anti-tumor efficacy study was performed on mice bearing either KB or HT1080 tumors. PTXOL HPPS was given once a week for 3 weeks by intravenous injection. Saline, PTX, PTXOL and HPPS were also given as controls.
The size of all tumors were tracked by monitoring tumor dimension twice a week and compared with their initial size. As shown by the tumor growth curve in Figure 4A , the tumor size continually increased following administration with HPPS and saline, while PTX and PTXOL effecand saline, while PTX and PTXOL effectively inhibited tumor growth. The final KB and HT1080 tumor volumes, at 21 days after the first dose were reduced to 85.6 ± 5.6 and 31.3 ± 1.5%, respectively for PTX treatment and 50.2 ± 21.7 and 57.4 ± 30.3%, respectively for PTXOL treatment. This showed both PTXOL and PTX inhibited the tumor growth of targeted and nontargeted cells. However, after loading PTXOL into HPPS, PTXOL HPPS was only able to suppress the tumor growth of the targeted cells, but not the nontargeted cells. The final KB tumor volume decreased to 63.4 ± 15.0, while HT1080 tumor volume increased to 1220.5 ± 531.1%. This was also evident in excised tumor images ( Figure 4B) showing the significant difference between in vivo therapeutic efficacy of PTXOL HPPS to targeted and nontargeted cells. Since some normal tissues, such as liver, also express a high level of SRB1, we tested liver function of the mice administrated with PTXOL HPPS to investigate the side effects of PTXOL HPPS on normal tissues. When compared with the saline control mice, no significant liver function damage was detected under our in vivo experimental conditions (SupplementAry tABle 1 ). Collectively, these in vivo data are consistent with the in vitro findings and provided convincing evidence that HPPS is not only able to effectively deliver anticancer drugs to targeted cells, but is also capable of attenuating the damage to nontargeted cells, resulting in an improved therapeutic index.
n Validation of HPPS's biocompatibility To further support the potential clinical utility of HPPS for anticancer drug delivery, we evaluated its acute toxicity by intravenously administering nude mice with 2000 mg·kg -1 of HPPS (the highest single test dose limited according to US FDA guidelines) and assessing its behavioral, biochemical and physical effects. Mice injected with 0.5 ml of saline served as controls. The HPPS treated groups did not show any abnormality in behavior. When compared with saline controls, the HPPS treated group did not show any measurable adverse effect on blood cells or liver function at 1, 8 and 15 days postinjection ( Figure 5) . The peripheral blood cells including white blood cells, red blood cells and platelets were all within the normal range. Analysis of liver enzymes such as alanine aminotransferase and alkaline phosphatase did not show potential toxicity. Furthermore, within 21 days, the body weight of the HPPS-treated group did not decrease and was not significantly different to that of the control group (p>0.5) (Figure 6A) . Finally, morphological and pathological examinations of the organs (Figure 6B ) revealed that there was no potential toxicity or damage to the heart, liver, kidney, spleen and lung as no necrosis, inflammatory reactions, fibrosis or local fatty degeneration were observed in the tissues after 21 days treatment. These data provide strong evidence that HPPS is a safe vehicle for drug delivery.
Discussion
Developing nanoparticle carriers to transport a large bolus of drug molecules into cytosolic compartments of cancer cells has become a highly active research area in nanomedicine [25] . This is because the sites of action for most cancer drugs are often cytosolic organelles and the cytosolic delivery might offer a means to evade efflux transporters such as multidrug resistance proteins and P-glycoproteins [26] . However, the challenges are abundant, for example:
Nanoparticle carriers are required to carry a large payload of drug that must be protected from extracellular degradation.
Nanoparticle internalization may lead to drug entrapment in closed vesicles (endosomes or phagosomes), resulting in decreased drug efficacy.
High-density lipoprotein is an endogenous nanocarrier possessing many attractive features for drug delivery (e.g., ultra small size, favorable surface properties and selective delivery of chol esterol esters to the cytosol of cells by the SRB1 mediated pathway). Using HDL for anticancer drug delivery has been reported by McConathy et al. [27, 28] . One potential hurdle in developing HDL as a clinically viable nanocarrier lies in the fact that lipoproteins are isolated from fresh donor plasma, which might result in batch-to-batch variation and pose some scale-up challenges. By mimicking HDL, the HPPS nanocarrier offers a new avenue for the delivery of intracellular active anticancer drugs because of its ability to directly transport a functional payload to the cytosol of cancer cells without going through endolysosomal trafficking, and its increased capability in its flexibility and scalability.
Here, we examined the capability of HPPS for anticancer drug delivery using PTXOL HPPS as a model. The hydrophobic core of HPPS car-
The hydrophobic core of HPPS carries a high payload of PTXOL (120 PTXOL/per particle) while maintaining its size and monodiswhile maintaining its size and monodispersity ( Figure 1C) . PTXOL HPPS is stable in both For functional studies of PTXOL HPPS on targeted cells (SRB1 + ), the effi cient therathe efficient therapeutic response was achieved presumably due to both the SRB1-mediated cytosolic payload delivery and the long circulation half-life of HPPS [10] . By using a surrogate fluorescent payload, the SRB1-specificity of HPPS was reaffirmed. Furthermore, flow cytometry data revealed a significant contrast in the speed of HPPS payload delivery between targeted versus nontargeted cells. The majority of HPPS payload (60% maximum cell-associated fluorescence) was delivered to targeted cells within storage conditions (4°C) (SupplementAry Figure 2A) and in serum at 37°C (SupplementAry Figure 2B) . Like liposomes and other lipid nanoparticles, HPPS is also highly biocompatible. Evidence of the biocompatibility of the HPPS was obtained from an in vivo acute toxicity test. At the very high intra-. At the very high intraAt the very high intravenous dose of 2000 mg·kg -1 , the HPPS-treated groups showed no abnormality in behavior, no measurable adverse effect on blood cells and liver function, no decrease in body weight, and no toxicity or damage to main organs, providing strong evidence that HPPS is a safe nanocarrier for lipophilic drug delivery. 30 min, whereas only 7% of HPPS payload was associated with nontargeted cells within the same timeframe (Figure 2) . Compared with the distribution half-life (0.34 h) and the elimina-(0.34 h) and the eliminaand the elimina-elimination half-life (5.8 h) of Taxol ® (the Cremophor EL formulation of PTX) [29] , using HPPS to deliver PTXOL can prolong drug blood circulation, with a payload distribution half-life of 2.6 h and an elimination half-life of 17.6 h (SupplementAry Figure 3) , thus providing more time for the PTXOL HPPS to reach its target site to improve the targeting delivery efficiency. Therefore, HPPS can be used to effectively deliver anticancer drugs to targeted cancer cells.
A key finding of this study is the marked attenuation of in vivo cytotoxicity of PTXOL HPPS against nontargeted cells with the SRB1 -tumor (HT1080) used as a model. The highly protective function of PTXOL HPPS to non-PTXOL HPPS to nonto nontargeted cells is likely due to the drug-shielding ability of HPPS. It was evident that PTXOL HPPS significantly reduced the cytotoxicity of PTXOL to HT1080 cells (SRB1 -), which was more sensitive to PTXOL treatment than KB cells (SRB1 + ) (Figure 3 ). The attractive properties of HPPS make it a powerful nanoparticle platform for anticancer drug delivery. In our previous studies, EGFconjugated HPPS showed a coordinated dual receptor (EGF receptor and SRB1) targeting phenomenon leading to enhanced payload delivery [30] . Furthermore, HPPS has been successfully loaded with either f luorescent dye or photodynamic therapy agents [16] . The combined diagnostic and therapeutic use of targeted HPPS nanoparticle platforms enables image-guided drug delivery, thus providing new potentials for clinical cancer diagnosis and treatment.
Conclusion
In summary, HPPS selectively delivered high payload of PTXOL to tumor cells through a direct cytosolic transport mechanism, inducing effective therapeutic activity only to targeted cells while attenuating cytotoxicity of anticancer drugs to nontargeted cells. The selective protection provides a promising strategy to reduce therapeutic side effects and increase clinical tolerable doses, which could ultimately lead to the improved impact of chemotherapy.
Future perspective
The direct cytosolic delivery and the drugshielding ability of HPPS make it a powerful nanoparticle platform for anticancer drug delivery. Besides targeting to its natural SRB1 receptor, HPPS could be redirected to other tumor specific biomarkers (e.g., EGF recep-EGF receptor). Furthermore, HPPS is capable of carry-). Furthermore, HPPS is capable of carryFurthermore, HPPS is capable of carrying a wide range of imaging and therapeutic agents including fluorescent probes, photodynamic therapy agents and siRNAs. The com-
The combined diagnostic and therapeutic use of targeted HPPS could enable image-guided drug delivery, providing new potentials for clinical cancer diagnosis and treatment.
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